Michael Gottlieb to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Michael Gottlieb has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.151
-
Idarucizumab for the Reversal of Dabigatran. Ann Emerg Med. 2017 May; 69(5):554-558.
Score: 0.151
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.